The Latest Psychedelics Articles from Streetwise Reports

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial

Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.

Biotech Co. Set To Reach New Highs

Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board

Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.

Addiction Therapy Company Secures Major UK Endorsement

Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.

Biotech at Good Entry Point for Investors, Analyst Says

Research Report
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Tags:  Psychedelics

Why One Fund Owns 13% of This Small-Cap Pharma

Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.

Showing Results: 1 to 8 of 8